CSL112 Efficacy and Safety: Systematic Review and Meta-Analysis of Six Clinical Trials

A systematic review and meta-analysis of six clinical trials (n=1,824) published from database inception to May 2025, evaluating the drug CSL112. The analysis, conducted by Umais Ahmed Shaikh and following PRISMA guidelines, found CSL112 significantly increased cholesterol efflux capacity and HDL-C levels with a favorable safety profile.

Use Cases

• Conducting meta-analyses on HDL-modulating therapies based on aggregated data from six trials
• Evaluating the safety profile of CSL112 based on reported serious adverse event and treatment-emergent adverse event rates
• Assessing the dose-response relationship for cholesterol efflux capacity based on the 6g dose results
• Designing future clinical trials for cardiovascular protection based on the identified efficacy endpoints

Strengths

• Analysis includes data from 1,824 participants across six trials
• Follows PRISMA guidelines and uses a random-effects model for statistical rigor
• Reports specific efficacy metrics including mean differences for total cholesterol efflux capacity (MD 11.90), ABCA1-dependent CEC (MD 5.88), and HDL-C levels (MD 6.89)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of studies from PubMed, Cochrane Library, Scopus, Google Scholar, and EMBASE.

Time Range

Database inception to May 2025

Freshness

Last updated 2026-05-13 06:24:40; freshness should be verified